ZYNE - ジナ―バ・ファ―マシュ―ティカルズ （Zynerba Pharmaceuticals Inc.）

DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at Cowen’s 43 rd Annual Health Care Conference on Wednesday, March 8, 2023, at 2:50 p.m. ET, and host investor meetings. The conference is being held at the Boston Marriott Copley Place in Boston, Mass.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Momentum Technology Stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Codiak BioSciences, Inc. (NASDAQ:CDAK) appeared first on Stocks Equity .

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Ensnaring stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -7.02%), Codiak BioSciences, Inc. (NASDAQ:CDAK -6.64%) appeared first on Stocks Equity .

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) marked $0.57 per share on Tuesday, down from a previous closing price of $0.58. While Zynerba Pharmaceuticals Inc. has underperformed by -1.78%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZYNE fell by -78.50%, with highs and lows ranging from $2.83 to […]

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) closed Tuesday at $0.63 per share, up from $0.61 a day earlier. While Zynerba Pharmaceuticals Inc. has overperformed by 2.66%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZYNE fell by -76.55%, with highs and lows ranging from $2.94 to $0.49, whereas […]

DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the Sofitel New York in New York City.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Overwhelming stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -3.48%), InspireMD, Inc. (NASDAQ:NSPR -0.57%) appeared first on Stocks Equity .

INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile

DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, … The post Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference appeared first on ForexTV .

DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24 th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022. A copy of the presentation slides will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/ . Additional meeting information can be found on the SSBP website at https://ssbp.org.uk/ .

DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the Sofitel New York in New York City.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Overwhelming stocks: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE -3.48%), InspireMD, Inc. (NASDAQ:NSPR -0.57%) appeared first on Stocks Equity .

INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile

DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, … The post Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference appeared first on ForexTV .

DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24 th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022. A copy of the presentation slides will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/ . Additional meeting information can be found on the SSBP website at https://ssbp.org.uk/ .